Breaking News Instant updates and real-time market news.

NERV

Minerva

$12.30

-0.15 (-1.20%)

08:34
10/18/16
10/18
08:34
10/18/16
08:34

Minerva poised to report positive data, says JMP Securities

JMP Securities analyst Jason Butler expects Phase 2b data on Minerva's MIN-101 drug for schizophrenia to be positive when it's reported this month. The analyst thinks that the data could include evidence that the drug "maintains control of positive symptoms." He reiterates a $17 price target and Outperform rating on the shares.

NERV Minerva
$12.30

-0.15 (-1.20%)

05/12/16
JEFF
05/12/16
INITIATION
Target $10
JEFF
Buy
Minerva assumed with a Buy at Jefferies
Jefferies analyst Chris Howerton assumed coverage of Minerva with a Buy rating and $10 price target.
05/26/16
JMPS
05/26/16
NO CHANGE
Target $17
JMPS
Outperform
Minerva price target raised to $17 from $10 at JMP Securities
JMP Securities analyst Jason Butler raised his price target for Minerva Neurosciences to $17 from $10 after the company's schizophrenia treatment met its endpoint in a Phase IIb study. The analyst has an Outperform rating on the shares. Minerva is trading up 176%, or $6.23, to $9.77 in afternoon trading.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.